Literature DB >> 16497572

SLOS carrier frequency in Poland as determined by screening for Trp151X and Val326Leu DHCR7 mutations.

E Ciara1, E Popowska, D Piekutowska-Abramczuk, D Jurkiewicz, M Borucka-Mankiewicz, Paweł Kowalski, B Goryluk-Kozakiewicz, M J M Nowaczyk, M Krajewska-Walasek.   

Abstract

Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder of cholesterol biosynthesis caused by mutations in the DHCR7 gene. Previous studies estimated the prevalence of SLOS between 1 in 10,000 to 1 in 70,358 based on case frequency surveys. Although panethnic, SLOS appears to be most frequent in Central European populations (Czech Republic 1 in 10,000, Slovakia 1 in 15,000 - 1 in 20,000). In Polish individuals with SLOS two DHCR7 mutations, c.452G>A (p.Trp151X) and c.976G>T (p.Val326Leu), account for 65.2% of all observed DHCR7 mutations. We analyzed 2169 samples for the p.Trp151X mutation and 2087 for the p.Val326Leu mutation. The combined carrier frequency of these two mutations of was 2.40+/-0.32%, yielding a calculated incidence of SLOS in Poland of 2.5 4x10(-4)-4.3 5x10(-4) (1 in 2,300 to 1 in 3,937) placing SLOS among the most common recessive genetic disorders in Poland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16497572     DOI: 10.1016/j.ejmg.2006.01.006

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  6 in total

Review 1.  Malformation syndromes caused by disorders of cholesterol synthesis.

Authors:  Forbes D Porter; Gail E Herman
Journal:  J Lipid Res       Date:  2010-10-07       Impact factor: 5.922

2.  Differences between predicted and established diagnoses of Smith-Lemli-Opitz syndrome in the Polish population: underdiagnosis or loss of affected fetuses?

Authors:  Aleksandra Jezela-Stanek; Elżbieta Ciara; Ewa Małunowicz; Krystyna Chrzanowska; Anna Latos-Bieleńska; Małgorzata Krajewska-Walasek
Journal:  J Inherit Metab Dis       Date:  2010-06-16       Impact factor: 4.982

3.  Increasing cholesterol synthesis in 7-dehydrosterol reductase (DHCR7) deficient mouse models through gene transfer.

Authors:  Xavier Matabosch; Lee Ying; Montserrat Serra; Christopher A Wassif; Forbes D Porter; Cedric Shackleton; Gordon Watson
Journal:  J Steroid Biochem Mol Biol       Date:  2010-08-26       Impact factor: 4.292

4.  Temporal changes in the brain lipidome during neurodevelopment of Smith-Lemli-Opitz syndrome mice.

Authors:  Amy Li; Kelly M Hines; Dylan H Ross; James W MacDonald; Libin Xu
Journal:  Analyst       Date:  2022-04-11       Impact factor: 5.227

5.  Cholesterol biosynthesis from birth to adulthood in a mouse model for 7-dehydrosterol reductase deficiency (Smith-Lemli-Opitz syndrome).

Authors:  Josep Marcos; Cedric H L Shackleton; Madhavee M Buddhikot; Forbes D Porter; Gordon L Watson
Journal:  Steroids       Date:  2007-07-13       Impact factor: 2.668

6.  A placebo-controlled trial of simvastatin therapy in Smith-Lemli-Opitz syndrome.

Authors:  Christopher A Wassif; Lisa Kratz; Susan E Sparks; Courtney Wheeler; Simona Bianconi; Andrea Gropman; Karim A Calis; Richard I Kelley; Elaine Tierney; Forbes D Porter
Journal:  Genet Med       Date:  2016-08-11       Impact factor: 8.822

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.